Advertisement

The Role of Pharmacy Refill Measures in Assessing Adherence and Predicting HIV Disease Markers in Youth with Perinatally-Acquired HIV (PHIV)

  • Cenk Yildirim
  • Patricia A. Garvie
  • Miriam Chernoff
  • Megan L. Wilkins
  • E. Doyle Patton
  • Paige L. Williams
  • Sharon L. NicholsEmail author
  • for the Memory and Executive Functioning Study of the Pediatric HIV/AIDS Cohort Study
Original Paper
  • 67 Downloads

Abstract

Antiretroviral (ARV) adherence is critical in monitoring disease response in youth with perinatally-acquired HIV (PHIV). We used pharmacy refill (PR) information for PHIV youth from the PHACS Memory Sub-study to calculate medication availability over 2, 4, and 6 months. PR, a proxy of adherence, was compared with self-reported 7-day adherence in predicting suppressed viral load (SVL < 400 copies/mL) and higher CD4% (≥ 25%). Among 159 PHIV youth, 79% were adherent by 7-day recall, and 62, 55, and 48% by PR over 2, 4, and 6 months, respectively. Agreement between 7-day recall and PR adherence was weak (Kappa = 0.09–0.25). In adjusted logistic regression models, adherence showed associations with SVL for 7-day recall (OR 2.78, 95% CI 1.08, 7.15) and all PR coverage periods (6-month: OR 3.24, 95% CI 1.22, 8.65). Similar associations were observed with higher CD4%. PR measures were predictive of study retention. Findings suggest a possibly independent role of PR adherence measures.

Keywords

ARV adherence Pediatric HIV Pharmacy refill Self-report Appointment adherence 

Notes

Acknowledgements

The authors extend their gratitude to Kunjal Patel, DSc, MPH, Senior Research Scientist, Harvard T.H. Chan School of Public Health, Department of Epidemiology, for her valuable consultation to the statistical analyses.

Funding

The Pediatric HIV/AIDS Cohort Study (PHACS) Memory and Executive Functioning substudy was supported by the National Institute of Mental Health (MH084794; PI: Sharon Nichols). Data analysis services were provided by the Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health (PI: Paige Williams); data management services were provided by Frontier Science and Technology Research Foundation (PI: Suzanne Siminski); and regulatory services and logistical support were provided by Westat, Inc. (PI: Julie Davidson). The Pediatric HIV/AIDS Cohort Study (PHACS) was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development with co-funding from the National Institute on Drug Abuse, the National Institute of Allergy and Infectious Diseases, the Office of AIDS Research, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, the National Institute on Deafness and Other Communication Disorders, the National Heart Lung and Blood Institute, the National Institute of Dental and Craniofacial Research, and the National Institute on Alcohol Abuse and Alcoholism, through cooperative agreements with the Harvard University T.H. Chan School of Public Health (HD052102) (Principal Investigator: George Seage; Project Director: Julie Alperen) and the Tulane University School of Medicine (HD052104) (Principal Investigator: Russell Van Dyke; Co-Principal Investigators: Kenneth Rich, Ellen Chadwick; Project Director: Patrick Davis).

We thank the children and families for their participation in the Memory/EF Sub-study and PHACS and the individuals and institutions involved in the conduct of these studies. The following institutions, clinical site investigators and staff participated in conducting PHACS AMP; sites participating in the Memory Study and the site PI are marked with an asterisk. In alphabetical order: Ann & Robert H. Lurie Children’s Hospital of Chicago*: Ram Yogev, Margaret Ann Sanders, Kathleen Malee*, Scott Hunter; Baylor College of Medicine*: William Shearer, Mary Paul, Norma Cooper, Lynnette Harris*; Bronx Lebanon Hospital Center: Murli Purswani, Mahboobullah Baig, Anna Cintron; Children’s Diagnostic & Treatment Center*: Ana Puga, Sandra Navarro, Patricia Garvie*, James Blood; Children’s Hospital, Boston*: Sandra Burchett, Nancy Karthas, Betsy Kammerer*; Jacobi Medical Center*: Andrew Wiznia, Marlene Burey, Molly Nozyce*; Rutgers - New Jersey Medical School: Arry Dieudonne, Linda Bettica, Susan Adubato; St. Christopher’s Hospital for Children: Janet Chen, Maria Garcia Bulkley, Latreaca Ivey, Mitzie Grant; St. Jude Children’s Research Hospital*: Katherine Knapp, Kim Allison, Megan Wilkins*; San Juan Hospital/Department of Pediatrics: Midnela Acevedo-Flores, Heida Rios, Vivian Olivera; Tulane University Health Sciences Center*: Margarita Silio, Medea Jones, Patricia Sirois*; University of California, San Diego*: Stephen Spector, Kim Norris, Sharon Nichols*; University of Colorado Denver Health Sciences Center: Elizabeth McFarland, Alisa Katai, Jennifer Dunn, Suzanne Paul; University of Miami: Gwendolyn Scott, Patricia Bryan, Elizabeth Willen

Note: The conclusions and opinions expressed in this article are those of the authors and do not necessarily reflect those of the National Institutes of Health or the U.S. Department of Health and Human Services.

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflicts of interest to report.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Supplementary material

10461_2019_2468_MOESM1_ESM.docx (23 kb)
Supplementary material 1 (DOCX 23 kb)
10461_2019_2468_MOESM2_ESM.tiff (1.6 mb)
Supplementary material 2 (TIFF 1622 kb)
10461_2019_2468_MOESM3_ESM.docx (15 kb)
Supplementary material 3 (DOCX 15 kb)
10461_2019_2468_MOESM4_ESM.docx (19 kb)
Supplementary material 4 (DOCX 19 kb)

References

  1. 1.
    Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.CrossRefGoogle Scholar
  2. 2.
    Zanoni BC, Mayer KH. The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDs. 2014;28(3):128–35.CrossRefGoogle Scholar
  3. 3.
    Neilan AM, Karalius B, Patel K, Van Dyke RB, Abzug MJ, Agwu AL, et al. Association of risk of viremia, immunosuppression, serious clinical events, and mortality with increasing age in perinatally human immunodeficiency virus-infected youth. JAMA Pediatr. 2017;171(5):450–60.CrossRefGoogle Scholar
  4. 4.
    Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2009;6(4):194–200.CrossRefGoogle Scholar
  5. 5.
    Kacanek D, Angelidou K, Williams PL, Chernoff M, Gadow KD, Nachman S, et al. Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study. Aids. 2015;29(10):1227–37.CrossRefGoogle Scholar
  6. 6.
    Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 2007;119(6):e1371–83.CrossRefGoogle Scholar
  7. 7.
    Williams PL, Storm D, Montepiedra G, Nichols S, Kammerer B, Sirois PA, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics. 2006;118(6):e1745–57.CrossRefGoogle Scholar
  8. 8.
    Buchanan AL, Montepiedra G, Sirois PA, Kammerer B, Garvie PA, Storm DS, et al. Barriers to medication adherence in HIV-infected children and youth based on self- and caregiver report. Pediatrics. 2012;129(5):e1244–51.CrossRefGoogle Scholar
  9. 9.
    Ingerski LM, Hente EA, Modi AC, Hommel KA. Electronic measurement of medication adherence in pediatric chronic illness: a review of measures. J Pediatr. 2011;159(4):528–34.CrossRefGoogle Scholar
  10. 10.
    van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89(9):632–9.CrossRefGoogle Scholar
  11. 11.
    Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.CrossRefGoogle Scholar
  12. 12.
    Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284–97.CrossRefGoogle Scholar
  13. 13.
    Usitalo A, Leister E, Tassiopoulos K, Allison S, Malee K, Paul ME, et al. Relationship between viral load and self-report measures of medication adherence among youth with perinatal HIV infection. AIDS Care. 2014;26(1):107–15.CrossRefGoogle Scholar
  14. 14.
    Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470–82.CrossRefGoogle Scholar
  15. 15.
    Wagner G. Utility of self-reported antiretroviral adherence: comment on Simoni et al. (2006). AIDS Behav. 2006;10(3):247–8.CrossRefGoogle Scholar
  16. 16.
    Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother. 2009;43(3):413–22.CrossRefGoogle Scholar
  17. 17.
    Farley J, Hines S, Musk A, Ferrus S, Tepper V. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. J Acquir Immune Defic Syndr. 2003;33(2):211–8.CrossRefGoogle Scholar
  18. 18.
    Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40(7–8):1280–8.CrossRefGoogle Scholar
  19. 19.
    Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4(4):187–91.CrossRefGoogle Scholar
  20. 20.
    Andrade AS, Deutsch R, Duarte NA, Marcotte TD, Umlauf A, et al. Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons. J Acquir Immune Defic Syndr. 2013;62(3):282–92.CrossRefGoogle Scholar
  21. 21.
    Lehmann A, Aslani P, Ahmed R, Celio J, Gauchet A, Bedouch P, et al. Assessing medication adherence: options to consider. Int J Clin Pharm. 2014;36(1):55–69.CrossRefGoogle Scholar
  22. 22.
    Sangeda RZ, Mosha F, Prosperi M, Aboud S, Vercauteren J, Camacho RJ, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health. 2014;14:1035.CrossRefGoogle Scholar
  23. 23.
    Zogg JB, Woods SP, Weber E, Iudicello JE, Dawson MS, Grant I, et al. HIV-associated prospective memory impairment in the laboratory predicts failures on a semi-naturalistic measure of health care compliance. Clin Neuropsychol. 2010;24(6):945–62.CrossRefGoogle Scholar
  24. 24.
    Albert SM, Weber CM, Todak G, Polanco C, Clouse R, McElhiney M, et al. An observed performance test of medication management ability in HIV: relation to neuropsychological status and medication outcomes. AIDS Behav. 1999;3:121–8.CrossRefGoogle Scholar
  25. 25.
    Ettenhofer ML, Foley J, Castellon SA, Hinkin CH. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology. 2010;74(15):1217–22.CrossRefGoogle Scholar
  26. 26.
    Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944–50.CrossRefGoogle Scholar
  27. 27.
    Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. Aids. 2004;18(Suppl 1):S19–25.CrossRefGoogle Scholar
  28. 28.
    Thames AD, Arentoft A, Rivera-Mindt M, Hinkin CH. Functional disability in medication management and driving among individuals with HIV: a 1-year follow-up study. J Clin Exp Neuropsychol. 2013;35(1):49–58.CrossRefGoogle Scholar
  29. 29.
    Wolf MS, Curtis LM, Wilson EA, Revelle W, Waite KR, Smith SG, et al. Literacy, cognitive function, and health: results of the LitCog study. J Gen Intern Med. 2012;27(10):1300–7.CrossRefGoogle Scholar
  30. 30.
    Waldrop-Valverde D, Guo Y, Ownby RL, Rodriguez A, Jones DL. Risk and protective factors for retention in HIV care. AIDS Behav. 2014;18(8):1483–91.CrossRefGoogle Scholar
  31. 31.
    de Boer IM, Prins JM, Sprangers MA, Nieuwkerk PT. Using different calculations of pharmacy refill adherence to predict virological failure among HIV-infected patients. J Acquir Immune Defic Syndr. 2010;55(5):635–40.CrossRefGoogle Scholar
  32. 32.
    Saberi P, Caswell N, Amodio-Groton M, Alpert P. Pharmacy-refill measure of adherence to efavirenz can predict maintenance of HIV viral suppression. AIDS care. 2008;20(6):741–5.CrossRefGoogle Scholar
  33. 33.
    Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57(10):1107–10.CrossRefGoogle Scholar
  34. 34.
    Acri TL, Grossberg RM, Gross R. How long is the right interval for assessing antiretroviral pharmacy refill adherence? J Acquir Immune Defic Syndr. 2010;54(5):e16–8.CrossRefGoogle Scholar
  35. 35.
    Abah IO, Ojeh VB, Musa J, Ugoagwu P, Agaba PA, Agbaji O, et al. Clinical utility of pharmacy-based adherence measurement in predicting virologic outcomes in an adult HIV-infected cohort in Jos, North Central Nigeria. J Int Assoc Provid AIDS Care. 2016;15(1):77–83.CrossRefGoogle Scholar
  36. 36.
    Ernesto AS, Lemos RM, Huehara MI, Morcillo AM, Dos Santos Vilela MM, Silva MT. Usefulness of pharmacy dispensing records in the evaluation of adherence to antiretroviral therapy in Brazilian children and adolescents. Braz J Infectious Dis. 2012;16(4):315–20.CrossRefGoogle Scholar
  37. 37.
    Marhefka SL, Farley JJ, Rodrigue JR, Sandrik LL, Sleasman JW, Tepper VJ. Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP). AIDS Care. 2004;16(3):323–38.CrossRefGoogle Scholar
  38. 38.
    Katko E, Johnson GM, Fowler SL, Turner RB. Assessment of adherence with medications in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2001;20(12):1174–6.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Cenk Yildirim
    • 1
  • Patricia A. Garvie
    • 2
  • Miriam Chernoff
    • 1
  • Megan L. Wilkins
    • 3
  • E. Doyle Patton
    • 4
  • Paige L. Williams
    • 1
    • 5
  • Sharon L. Nichols
    • 6
    Email author
  • for the Memory and Executive Functioning Study of the Pediatric HIV/AIDS Cohort Study
  1. 1.Center for Biostatistics in AIDS ResearchHarvard T. H. Chan School of Public HealthBostonUSA
  2. 2.Research DepartmentChildren’s Diagnostic & Treatment CenterFort LauderdaleUSA
  3. 3.St. Jude Children’s Research HospitalMemphisUSA
  4. 4.Patton Psychology Associates, Inc.AventuraUSA
  5. 5.Departments of Biostatistics and EpidemiologyHarvard T. H. Chan School of Public HealthBostonUSA
  6. 6.Department of NeurosciencesUniversity of California, San DiegoLa JollaUSA

Personalised recommendations